India $122 mn stimulus to accelerate Covid-19 vaccines |
India`s Ministry of Science & Technology on 29th November announced a third stimulus package of US$ 121.6 million for the Mission COVID Suraksha - the Indian Covid-19 Vaccine Development Mission. It marks Modi Government`s commitment to accelerate development of approximately five to six Covid-19 vaccine candidates currently in the running. The grant will be provided to the Department of Biotechnology (DBT) for Research & Development of Indian Covid-19 vaccines. It will ensure speeding up the process for licensure and market entry of vaccines after due approvals by regulatory authorities. The covid-19 Vaccine Development Mission with end-to-end focus from preclinical development through clinical development and manufacturing and regulatory facilitation for deployment, will consolidate all available and funded resources towards accelerated product development. The important objectives of the fund are to accelerate pre-clinical and clinical development; licensure of Covid-19 vaccine candidates that are currently in clinical stages or ready to enter clinical stage of development, establish clinical trial sites, and strengthen the existing immunoassay laboratories, central laboratories and suitable facilities for animal studies, production facilities and other testing facilities to support Covid-19 vaccine development. The other important objective will be supporting development of common harmonized protocols, training, data management systems, regulatory submissions, internal and external quality management systems and accreditations.
|
|
|
|
|
